Lung Cancer Mutation Consortium

The Lung Cancer Mutation Consortium (LCMC) is a collaborative effort among medical researchers and doctors aimed at improving lung cancer treatment. It focuses on identifying specific genetic changes, or mutations, in a patient’s tumor. Understanding these mutations helps doctors choose targeted therapies that are more effective for each individual’s cancer. By analyzing a large number of tumors, the consortium advances personalized medicine, leading to better outcomes and more tailored treatments for lung cancer patients.